FDA.reportPublic FDA data

1 ML omalizumab-igec 150 MG/ML Prefilled Syringe

RxCUI
2726001
RxNorm name
1 ML omalizumab-igec 150 MG/ML Prefilled Syringe
Display name
1 ML omalizumab-igec 150 MG/ML Prefilled Syringe
Full name
1 ML omalizumab-igec 150 MG/ML Prefilled Syringe
Term type
SCD
Status
DailyMed mapping
Updated
2026-06-04 23:39:11

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 1 matching rows.

Set ID, RxNorm mappings, Terms table
Set IDRxNorm mappingsTermsSPL versionLabelEffective
a2075490-d8e7-4c23-8b2e-8f2cd5a67948omalizumab-igec 150 MG in 1 ML Prefilled Syringe [PSN] · 1 ML omalizumab-igec 150 MG/ML Prefilled Syringe [SCD] · omalizumab-igec 150 MG per 1 ML Prefilled Syringe [SY]34These highlights do not include all the information needed to use OMALIZUMAB-IGEC safely and effectively. See full prescribing information for OMALIZUMAB-IGEC. OMALIZUMAB-IGEC injection, for subcutaneous use Initial U.S. Approval: 2025 Omalizumab-igec is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product and that there are no clinically meaningful differences between the20251205